The incidence of hepatocellular carcinoma, particularly among individuals aged 70 and above, poses significant clinical challenges due to comorbidities and the reduced physiological resilience of this population. Standard therapeutic approaches, such as TACE, though widely used, often manifest considerable adverse effects with suboptimal long-term outcomes in elderly patients. Against this backdrop, the present retrospective analysis leverages clinical data from 82 elderly uHCC patients treated at Wuhan Union Hospital between 2019 and 2022, stratified into two cohorts receiving either HAIC combined with lenvatinib or TACE monotherapy.

Dissecting the molecular underpinnings of this combined regimen reveals a synergistic mechanism where raltitrexed, a thymidylate synthase inhibitor, and oxaliplatin, a platinum-based chemotherapeutic agent, deliver potent cytotoxicity directly to the hepatic tumor via arterial infusion. Concurrently, lenvatinib’s antiangiogenic properties disrupt tumor vasculature and inhibit key signaling pathways essential for tumor growth and proliferation, thereby augmenting the cytotoxic impact of HAIC.

Quantitative outcomes from the study underscore the superiority of the HAIC plus lenvatinib combination. The objective response rate (ORR), a critical measure of tumor shrinkage post-therapy, was significantly higher at 61.5% in the combination group versus 37.2% in patients undergoing TACE. Similarly, the disease control rate (DCR), encompassing both tumor response and stabilization, improved dramatically to 82.1% compared to 58.1% in the control group, suggesting enhanced disease management efficacy.

Crucially, survival metrics emphasize the real-world benefit of this novel therapeutic strategy. Median progression-free survival (mPFS)—the interval during which patients show no disease progression—was extended to 9.2 months for those receiving RALOX-HAIC plus lenvatinib, more than doubling the 4.6 months observed in the TACE cohort. Even more striking was the prolongation of overall survival (OS), with the experimental group achieving a median of 18.1 months compared to just 10.6 months in the TACE group, indicating a nearly 70% improvement.

Safety and tolerability analyses further delineate the clinical advantage of the combination regimen, revealing substantially fewer incidences of abdominal pain and fever relative to TACE-treated patients. While hand-foot syndrome, a recognized adverse effect associated with lenvatinib, was more frequent in the combination group (15.4% versus none in TACE), the severity did not escalate into critical toxicity, with grade 3 or 4 cases remaining rare and statistically insignificant.

The study’s retrospective design, though limiting causal inferences, provides robust real-world evidence supporting the integration of systemic targeted therapy with localized chemotherapy infusion for challenging hepatocellular carcinoma cases in an elderly demographic. Importantly, this combined approach opens avenues for tailored oncological care that balances efficacy with quality of life considerations for a vulnerable patient subset.

At a cellular level, the therapeutic approach exploits the hepatic artery’s favorable pharmacokinetics for delivering high-dose chemotherapeutic agents directly to tumor sites, reducing systemic exposure and minimizing collateral damage to healthy tissues. Raltitrexed’s action inhibits DNA synthesis, while oxaliplatin induces DNA cross-links, together crippling cancer cell replication. Lenvatinib’s inhibition of VEGFR, FGFR, and PDGFR pathways simultaneously halts angiogenesis, cutting off the tumor’s blood supply essential for its sustenance.

This multi-modal assault disrupts tumor microenvironment homeostasis, impeding progression and metastatic potential, which is paramount in advanced unresectable cases where surgical options are precluded. Moreover, the favorable safety profile observed indicates that elderly patients tolerate the combination well, an aspect crucial for adherence and sustained therapeutic success in geriatric oncology.

The implications of this study herald a paradigm shift in managing elderly patients with uHCC, traditionally a cohort fraught with therapeutic dilemmas due to frailty and comorbid disease burdens. By leveraging a carefully calibrated combination of local and systemic agents, clinicians can now envisage improved survival outcomes without compromising patient safety, thereby addressing a critical unmet need in hepatic oncology.

Furthermore, the findings suggest potential applicability beyond elderly populations, warranting exploration in younger cohorts and in diverse clinical settings. The interplay between HAIC-induced cytotoxicity and lenvatinib’s molecular targeting invites translational research to optimize dosing regimens, sequencing, and combination partners to enhance therapeutic indices.

In addition to efficacy and safety, patient-centric aspects such as treatment convenience, hospitalization time, and quality of life parameters merit future prospective studies. The retrospective data from the Wuhan Union Hospital cohort provide a compelling foundation upon which randomized controlled trials can be designed to validate these promising results.

This therapeutic strategy also aligns with precision medicine trends, where molecular profiling and tumor biology insights inform individualized treatment plans. As hepatocellular carcinoma often harbors heterogeneous genetic alterations, combinatorial regimens like RALOX-HAIC plus lenvatinib may prove effective in overcoming resistance mechanisms inherent in monotherapies.

Moreover, the integration of real-world clinical data underscores the importance of observational studies in generating actionable knowledge, particularly when rapid translation to practice is critical for patient outcomes. The comprehensive analysis of adverse events alongside survival data strengthens the clinical relevance of the findings.

In conclusion, the study pioneers a compelling therapeutic avenue that combines the local high-dose chemotherapy benefits of RALOX-HAIC with the systemic inhibitory effects of lenvatinib to substantially improve treatment responses and survival in elderly uHCC patients. This advancement marks a significant stride toward more effective, safer, and patient-tailored management of unresectable hepatocellular carcinoma, promising a beacon of hope for a patient population in dire need of optimized cancer care.

Subject of Research: Efficacy and safety of RALOX-HAIC combined with lenvatinib in elderly patients with unresectable hepatocellular carcinoma

Article Title: RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma

Article References:
Lu, H., Gao, Y., Xia, X. et al. RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma. BMC Cancer 25, 882 (2025). https://doi.org/10.1186/s12885-025-14274-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14274-x

Hepatocellular carcinoma remains one of the most lethal malignancies worldwide, largely due to late-stage diagnosis and limited therapeutic options once tumors reach an unresectable stage. Systemic therapies, including targeted agents and immune checkpoint inhibitors, have shown survival benefits but often fall short in achieving significant tumor downstaging. HAIC, which delivers high concentrations of chemotherapeutic agents directly into the liver’s arterial supply, has increasingly garnered attention as a locoregional approach with the potential to reduce tumor burden effectively while minimizing systemic toxicity.

This novel trial enrolled 19 patients diagnosed with advanced uHCC, all initially deemed unsuitable candidates for surgery. Participants received a carefully timed regimen combining apatinib, camrelizumab, and HAIC administered with the FOLFOX chemotherapy protocol, which includes oxaliplatin, leucovorin, and fluorouracil. The treatment cycles spanned 21-day intervals, extending to a maximum of eight cycles to maximize clinical response. Such an approach reflects an intricate balance of leveraging local chemotherapy infusion alongside systemic immune activation and angiogenesis inhibition.

The most striking outcome from this study was the achievement of conversion to resectability in nearly three-quarters of the patients. Specifically, 14 out of 19 participants exhibited sufficient tumor regression and favorable biological responses, making surgical intervention viable. Among them, nine patients proceeded to margin-free (R0) resections—surgical removals with no residual cancer cells detected at the margins—a gold standard for curative intent in oncologic surgery. These results underscore the potential that aggressive multimodal treatment harbors in transforming the clinical trajectory of traditionally inoperable liver cancers.

Notably, the pathological assessments post-surgery revealed that a third of these resected tumors demonstrated a major pathological response to the treatment, including two cases achieving complete pathological remission. This indicates that the combination therapy not only shrinks tumors radiographically but can also eliminate microscopic disease, an encouraging sign for long-term survival prospects. Furthermore, objective response rates approximated 47%, with disease control rates nearing 90%, according to RECIST (Response Evaluation Criteria In Solid Tumors) standards, highlighting a robust anti-tumor effect.

Importantly, the safety profile of this demanding regimen was manageable, albeit with considerable but expected toxicities. Over 70% of patients experienced grade 3 or higher treatment-related adverse events. Elevated liver enzymes and increased lymphocyte counts were the most frequent severe side effects. Encouragingly, no treatment-related mortality occurred, affirming that with vigilant monitoring and supportive care, this therapeutic strategy is tolerable for a majority of patients.

The underlying scientific rationale for this triple combination rests on synergistic mechanisms: HAIC delivers concentrated cytotoxic drugs directly to tumor vasculature, apatinib acts as a potent anti-angiogenic agent restricting tumor blood supply by inhibiting vascular endothelial growth factor receptor-2 (VEGFR-2), and camrelizumab unleashes the immune system by blocking PD-1 immune checkpoints. Together, these agents mount a multifaceted attack capable of overcoming tumor immune evasion and chemoresistance, which are critical challenges in advanced HCC.

This trial’s findings pave the way for further exploration of HAIC combined with immunotherapy and targeted agents as a conversion strategy, opening new doors to potentially curative surgery for patients previously resigned to palliative care. While survival data remain immature, the initial signals of tumor control and margin-negative resection bode well for improved outcomes. Future randomized controlled trials will be essential to validate these findings, optimize dosing schedules, and refine patient selection criteria.

Given the complexity of hepatocellular carcinoma’s biology and the heterogeneous nature of patient responses, the multidisciplinary integration of locoregional treatment, targeted therapy, and immunotherapy represents a tailored therapeutic frontier. This approach underscores a shift toward personalized oncology where combination regimens can be fine-tuned to elicit maximal tumor regression while maintaining quality of life.

The study also raises intriguing questions about the timing and sequencing of therapies. Administering camrelizumab shortly after apatinib initiation and preceding hepatic arterial infusion likely maximizes immune modulation and tumor microenvironment alteration, facilitating enhanced efficacy. Such precise coordination highlights the importance of understanding pharmacodynamics and immune interactions in devising effective treatment algorithms.

Beyond clinical efficacy, the trial exemplifies how advancements in interventional radiology and immuno-oncology can converge to extend the boundaries of cancer care. Hepatic artery infusion requires specialized expertise and infrastructure, underscoring the need for centers of excellence capable of delivering complex multimodal therapies safely and effectively.

While this treatment strategy currently applies to a select cohort of patients with unresectable hepatocellular carcinoma, its success may inspire similar combinatory frameworks for other solid tumors where surgical options are limited by advanced disease. The concept of conversion therapy, pushing tumors from inoperable to operable states, embodies a proactive and aggressive stance in cancer management.

In summary, the integration of HAIC using the FOLFOX regimen with camrelizumab and apatinib represents a significant leap forward in the therapeutic landscape of advanced hepatocellular carcinoma. The trial’s encouraging outcomes justify continued investigation and hope for a new standard of care that can improve survival and quality of life for a challenging patient population. As the oncology community anticipates further data, this innovative treatment offers a beacon of optimism for patients facing limited options.

Subject of Research: Conversion therapy for unresectable hepatocellular carcinoma using hepatic arterial infusion chemotherapy combined with immune checkpoint inhibition and targeted therapy.

Article Title: Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.

Article References:
Yalikun, K., Li, Z., Zhang, J. et al. Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial. BMC Cancer 25, 838 (2025). https://doi.org/10.1186/s12885-025-14250-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14250-5

Hepatocellular carcinoma remains one of the most prevalent malignancies worldwide and carries a notoriously high recurrence rate following surgical resection. Such recurrences often present as unresectable lesions, demanding alternative therapeutic approaches. Despite advances in loco-regional therapies, no standardized treatment regimen currently exists for managing recurrent unresectable HCC, highlighting an urgent unmet clinical need.

The study, published in BMC Cancer, retrospectively analyzed clinical data from 83 patients diagnosed with recurrent unresectable HCC after initial surgery. The patients were stratified into three distinct treatment cohorts based on their regimens: a group receiving HAIC combined with TKIs and PD-1 inhibitors (HTP), a second group treated with TACE in combination with TKIs and PD-1 inhibitors (TTP), and a third control group undergoing TACE alone. This design enabled a robust comparative assessment of treatment efficacy and safety among cutting-edge combination therapies versus standard intervention.

HAIC and TACE are both hepatic artery-targeted therapies aimed at delivering chemotherapeutic agents directly to liver tumors, thereby maximizing local antitumor activity while limiting systemic toxicity. Combining these modalities with TKIs, which inhibit angiogenesis and tumor proliferation pathways, alongside PD-1 inhibitors that unleash anti-tumor immune responses, represents an innovative multimodal approach to tackle tumor progression on multiple fronts simultaneously.

The primary endpoint assessed was progression-free survival (PFS), a critical measure reflecting the duration during which patients remained free from disease advancement. Results revealed a marked improvement in median PFS among patients receiving combination therapy. Specifically, the HTP group demonstrated a median PFS of 13.7 months, substantially longer than the 9.2 months observed in the TTP group and dramatically exceeding the 2.5 months recorded for those treated with TACE alone. These findings underscore the additive benefit of incorporating both TKIs and PD-1 inhibitors alongside hepatic arterial infusion strategies.

Beyond survival metrics, tumor response was meticulously evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST), a standard for assessing therapeutic efficacy in HCC that accounts for changes in viable tumor tissue. The disease control rate (DCR), encompassing complete response (CR), partial response, and stable disease, was significantly higher in the HTP cohort at 89.7%, compared to 75.0% in the TTP group and only 50.0% with TACE monotherapy. The objective response rate (ORR), indicative of measurable tumor shrinkage, also favored combination regimens, reaching 44.8% and 35% in the HTP and TTP groups respectively, versus a mere 14.7% in the control group.

Remarkably, the incidence of complete response was restricted to the HTP group, with 17.2% of patients achieving this outcome. This contrasts starkly with a complete response rate of zero in both the TTP and TACE alone arms. Such results suggest that HAIC, when synergized with TKIs and PD-1 checkpoint blockade, may elicit profound antitumor effects potentially capable of eradicating clinically evident disease in a subset of patients.

Safety profiles across treatment arms were carefully monitored, revealing no occurrences of serious adverse reactions within the HTP and TTP groups. This highlights the tolerability of these combination regimens, which is pivotal considering the typically compromised hepatic reserve and overall frailty of advanced HCC patients. The absence of severe toxicity supports the feasibility of integrating immunotherapy and targeted agents with locoregional chemotherapy in clinical practice.

Mechanistically, the therapeutic synergy observed likely stems from complementary modes of action. TKIs suppress tumor angiogenesis and cellular proliferation, thereby restricting nutrient supply and direct tumor growth. PD-1 inhibitors enhance the host immune system’s capacity to recognize and destroy cancer cells by preventing immune checkpoint-mediated T cell exhaustion. Concurrently, HAIC and TACE deliver localized cytotoxic chemotherapy that induces tumor necrosis. This concerted attack disrupts the tumor microenvironment, potentially overcoming resistance mechanisms seen with monotherapy.

This study’s implications extend far beyond survival statistics. It emphasizes the evolving landscape of HCC treatment, where integrating systemic immunomodulation and targeted therapy with traditional intra-arterial chemotherapy heralds a new era of personalized oncology. Identifying patients most likely to benefit from such regimens remains an ongoing challenge, necessitating further biomarker-driven investigations.

Despite its retrospective design and relatively modest sample size, the research offers compelling evidence warranting prospective, randomized clinical trials to validate these findings. The ability to induce complete responses in previously refractory recurrent HCC patients could translate into durable remissions and improved overall survival, transforming standard care paradigms.

In summary, the combination of TKIs and PD-1 inhibitors with HAIC or TACE demonstrates superior efficacy and safety compared to TACE alone in treating recurrent unresectable hepatocellular carcinoma. Particularly, HAIC combined with these systemic agents achieves the highest complete response rates, shedding light on promising therapeutic avenues. As liver cancer continues to pose formidable clinical challenges, these findings pave the way toward more effective, multimodal treatment strategies that improve patient outcomes and quality of life.

Future research should aim to elucidate the molecular underpinnings driving response heterogeneity and resistance, optimize dosing schedules, and evaluate long-term survivorship benefits. Moreover, integrating advanced imaging modalities and liquid biopsy approaches may facilitate early detection of treatment response and recurrence, further refining clinical decision-making. Ultimately, multidisciplinary collaboration will be key to translating these scientific insights into routine clinical application.

The study stands as a testament to the rapidly advancing frontier of oncological therapeutics, underscoring the power of combining precision medicine, immunotherapy, and locoregional interventions. As these innovations converge, they offer renewed optimism for patients confronting the formidable challenge of recurrent unresectable hepatocellular carcinoma.

Subject of Research: Treatment efficacy and safety of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with hepatic arterial infusion chemotherapy/transarterial chemoembolization for recurrent unresectable hepatocellular carcinoma.

Article Title: The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Article References:
Deng, W., Xie, J., Wang, T. et al. The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma. BMC Cancer 25, 779 (2025). https://doi.org/10.1186/s12885-025-14185-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14185-x